Credit Suisse Ag Cyclerion Therapeutics, Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$2.37 - $7.14 $38,026 - $114,561	-16,045 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$2.46 - $5.84 $39,470 - $93,702	16,045 New	16,045 $42,000
Q4 2019 Feb 12, 2020	SELL	$1.8 - $13.43 $24,858 - $185,468	-13,810 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$8.12 - $14.54 $21,355 - $38,240	2,630 Added 23.52%	13,810 $167,000
Q2 2019 Aug 14, 2019	BUY	$9.6 - $22.85 $107,328 - $255,463	11,180 New	11,180 $128,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $97M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.